Trial Profile
A Single-center, Dose-escalation, Open-label Pilot Study to Evaluate the Safety and Tolerability of a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults Aged 18-65 Years in China
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 21 Sep 2016
Price :
$35
*
At a glance
- Drugs Staphylococcus aureus vaccine (Primary)
- Indications Staphylococcal infections
- Focus Adverse reactions
- 08 Sep 2016 Status changed from recruiting to completed.
- 25 Jul 2016 New trial record